169 results about "Naphthalene Derivative" patented technology

Compounds of the formulawhere the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

A novel electroluminescence polymer offers stable EL characteristics: it forms little aggregates and is less susceptible to morphological changes during and after film formation. The EL polymer comprises a binaphthyl derivative structural unit represented by the following formula (1a) and an aryl structural unit represented by the following formula (1b): wherein Ar is an aryl structural unit that can form an electroluminescent π-conjugated polymer; R1, R2, R3, and R4 are each independently a different functional group; the double bonds of the binaphthyl structural unit indicated by dashed lines and solid lines are each an unsaturated double bond or a saturated single bond; m and p are each independently an integer of 0 to 2; n and o are each independently an integer of 0 to 8; x is the molar fraction of the binaphthyl derivative structural units; and y is the molar fraction of the aryl structural units.

A naphthalene derivative having formula (1) is provided wherein cyclic structures Ar1 and Ar2 denote a benzene or naphthalene ring, X is a single bond or C1-C10 alkylene, m is 0 or 1, and n is such a natural number as to provide a molecular weight of up to 100,000. A material comprising the naphthalene derivative or a polymer comprising the naphthalene derivative is spin coated to form a resist bottom layer having improved properties. A pattern forming process in which a resist bottom layer formed by spin coating is combined with an inorganic hard mask formed by CVD is available.

A method for producing coated particles includes the steps of converting particles consisting of a compound of one of (a) a metal with a non-metal or (b) a semi-metal with a non-metal to an aerosol form; contacting the particles in aerosol form with a gas including at least one aromatic compound; and guiding the particles in aerosol form together with the gas through a plasma zone of a microwave plasma. The at least one aromatic compound is preferably selected from the group consisting of benzol, benzol derivatives, naphthalene, and naphthalene derivatives. The gas preferable further includes at least one metallocene which is preferably selected from the group consisting of ferrocene or magnesocene.

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G1, Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and / or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.

The present invention provides a compound of the following formula (I) below. This compound (I) can be produced by reacting a 2,2′-dimethylene bromide-1,1′-binaphthyl derivative, which can be produced by a relatively small number of processes, with an easily available secondary amine. This compound (I) is useful as a chiral phase-transfer catalyst.

Compounds of the formulawhere the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

A composition for forming a lower layer film comprises a polymer (A) having a naphthalene derivative structural unit shown by the following formula (1),wherein R1 represents a hydroxyl group and the like, X represents a substitutable alkylene group having 1 to 20 carbon atoms and the like, n represents 0 to 6, m represents 1 to 8, and n+m represents an integer from 1 to 8, provided that two or more R1s may be the same or different and two or more Xs may be the same or different.

The invention aims to provide a perylene derivative preparation process featuring satisfactory yields and improved preparation efficiency, a perylene derivative obtained by the process, and an organic EL device using the same. The object is achieved by a perylene derivative preparation process comprising subjecting to coupling reaction a 1,8-dihalogenated naphthalene derivative of the formula (1): wherein X is Cl, Br or I, R1 to R4, R11 and R12 each are hydrogen, alkyl, alkoxy, alkylthio, alkenyl, alkenyloxy, alkenylthio, aralkyl, aralkyloxy, aralkylthio, aryl, aryloxy, and arylthio radicals which may be substituted, amino radical, cyano radical, hydroxyl radical, —COOM1 radical (wherein M1 is hydrogen, alkyl, alkenyl, aralkyl or aryl), —COM2 radical (wherein M2 is hydrogen, alkyl, alkenyl, aralkyl, aryl or amino), or —OCOM3 radical (wherein M3 is alkyl, alkenyl, aralkyl or aryl), and at least two adjoining radicals selected from among R1 to R4, R11 and R12 may bond or fuse together to form a substituted or unsubstituted carbocyclic aliphatic ring, aromatic ring or fused aromatic ring with the carbon atoms on which they substitute, with the proviso that when the carbocyclic aliphatic ring, aromatic ring or fused aromatic ring has substituent radicals, the substituent radicals are the same as R1 to R4, R11 and R12, to thereby synthesize a perylene derivative of the formula (2): wherein R1′ to R4′, R11′ and R12′ are as defined for R1 to R4, R11 and R12 in formula (1), and R1 to R4, R11 and R12 and R1′ to R4′, R11′ and R12′ may be the same or different.

A naphthalene derivative having formula (1) is provided wherein Ar1 and Ar2 denote a benzene or naphthalene ring, and n is such a natural number as to provide a weight average molecular weight of up to 100,000. A material comprising the naphthalene derivative or a polymer comprising the naphthalene derivative is spin coated to form a resist bottom layer having improved properties. A pattern forming process in which a resist bottom layer formed by spin coating is combined with an inorganic hard mask formed by CVD is available.

An organometallic complex for an organic light-emitting layer and an organic light-emitting diode are provided. A naphthalene derivative as a ligand is introduced to the organometallic complex. The organic light-emitting diode uses the organometallic complex as a phosphorescent host material. The organic light-emitting diode exhibits high current efficiency, high power efficiency and long lifetime when compared to conventional devices using BAlq.

This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. They have the general formula (I)in which R1 represents hydrogen or C1-6 alkyl, and X represents —N(H)Y1, —(H)—C1-6 alkyleneY1, biphenyl or C1-6 alkyl substituted by biphenyl, and the group Y1 is an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

This invention relates to tetrahydro-naphthalene derivatives of formula (I)in which the variable groups are as defined in the specification and claims, and tautomeric and stereoisomeric forms and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. The compounds, pharmaceutical compositions containing them, and methods of treatment using them are disclosed and claimed.

Where Y, R1-R8 and R101-R108 are as defined in the specification. Compounds of formula (II) and methods of inhibiting the cytokine or biological activity of Macrophage Migrating Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as part of a combination therapy.